Madrigal Pharmaceuticals (MDGL) clinical trials: pipeline and status changes, no readout expected in the next 12 months
$MDGL · Madrigal Pharmaceuticals, Inc.Trials that could report in the next 12 months: 0BiopharmaCTG
Catalyst timeline
No upcoming catalysts tracked for MDGL. Estimated readout windows appear automatically as tracked trials approach their registered completion dates.
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resme… | Phase 3 | Active Not Recruitingenrolled, still running | NCT03900429 | |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outco… | Phase 3 | Active Not Recruitingenrolled, still running | NCT05500222 | |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3… | Phase 3 | Active Not Recruitingenrolled, still running | NCT04951219 | |
| Study of Resmetirom in Children and Adolescents With MASH | Phase 2 | Not Yet Recruitingnot open yet | NCT07763015 | |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MA… | Phase 2 | Recruitingstill enrolling patients | NCT07335601 |
Status-change history
Every ClinicalTrials.gov change recorded for MDGL's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is MDGL's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is MDGL's lead program in?
Phase 3 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.